期刊文献+

辛伐他汀对糖尿病大鼠肾组织中核因子-κB活性的影响 被引量:1

下载PDF
导出
摘要 目的探讨辛伐他汀实验性糖尿病大鼠肾组织中核转录因子-kappaB(NF-κB)的影响及其机制。方法将36只大鼠随机分为对照组、糖尿病组和糖尿病辛伐他汀处理组(治疗组).糖尿病组和治疗组以高糖、高脂饮食加小剂量链脲佐菌素(STZ)制备实验性糖尿病大鼠模型。采用免疫组织化学染色法检测各组大鼠肾组织中NF-κB和单核/巨噬细胞(ED1)的表达水平并作比较。结果糖尿病组大鼠肾组织中NF-κB和ED1表达较对照组明显增加。治疗组以辛伐他汀处理4周后,NF-κB活性降低(P<0.01),ED1浸润减轻(P<0.01),肾功能各指标及肾组织病理学损害改善。结论辛伐他汀的肾保护作用与降低肾组织中NF-κB的活性、减轻ED1浸润的抗炎作用有关.且不依赖其降血脂发挥作用。
出处 《临床肾脏病杂志》 2005年第1期18-21,F003,共5页 Journal Of Clinical Nephrology
  • 相关文献

参考文献11

  • 1刘冬舟,贾汝汉,丁国华.HMG—CoA还原酶抑制剂与肾脏保护[J].临床肾脏病杂志,2001,1(4):191-192. 被引量:4
  • 2高苹,贾汝汉,宋恩峰,褚瑰丽,丁国华.氟伐他汀、缬沙坦及两药合用对糖尿病大鼠肾小管间质病变的保护作用[J].中华肾脏病杂志,2004,20(3):218-219. 被引量:12
  • 3陈玲,贾汝汉,丁国华,刘红燕,杨定平,彭隽,田少江.缬草油对2型糖尿病大鼠肾脏的保护作用及其机制探讨[J].中华肾脏病杂志,2003,19(3):168-172. 被引量:42
  • 4Henke C, Marineili W,Jessurun J,et al. Macrophage production of basic fibroblast growth factor in the tibroproliferative disorder of alveolar fibrosis after lung injury. Am J Pathol, 1993, 143:1189-1199.
  • 5Nikolic Paterson DJ, Atkins RC. The role of macrophages in glomerulonephritis. Nephrol Dial Transplant. 2001, 16(Supp15):3-7.
  • 6Gueler F, Rong S, Park JK. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol. 2002,13:2288-2298.
  • 7Park JK, Muller DN, Mervaala EM. Cerivastatin prevents angiotensin Ⅱ-induced renal injury independent of blood pressure-and cholesterol lowering effects. Kidney Int, 2000 . 58 : 1420-1430.
  • 8Usui H, Shikata K, Matsuda M. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiolropic effects in rats. Nephrol Dial Transplant. 2003,18:265-272.
  • 9Guijarro C, Egido J. Transcription factor kappa B (NF-kappa B) and renal disease. Kidney Int. 2001 .59:415-424.
  • 10Ruiz Ortega M,Bustos C, Hernandez Presa MA. et al. Angiotensin Ⅱ participates in mononuclear ceil recruitment in experimental immune complex nephritis through nuclear {actor kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol, 1998,161:430-439.

二级参考文献39

  • 1陈磊,秦路平,郑汉臣.缬草的化学成分、植物资源和药理活性[J].药学实践杂志,2000,18(5):277-279. 被引量:15
  • 2Aoyama I, Shimokata K, Niwa T. An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats. Nephron,2002, 92: 635-651.
  • 3Usui H, Shikata K, Matsuda M, et al.HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant,2003, 18: 265-272.
  • 4Zoja C, Corna D, Rottoli D, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int, 2002, 61: 1635-1645.
  • 5Attman PO, Alau Povic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int, 1991, (Suppl)39:S16.
  • 6Kaiske BL, O'Donnell MP, Schmitz PG,et al. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int, 19937:880.
  • 7Samuelsson O, Aurell M, Knight-Gibson C, et al. Apo B-containing liopoproteins and the progression of renal insufficiency.Neplon, 1993, 63:279.
  • 8Guijarro C, Keane WF. Effects of lipids on the pathogenesis of progressive renal failure.Miner Electrolyte Metab, 1996, 22:147.
  • 9Lain KS, Cheng IK, Janus ED, et al.Cholesterol-lowering therapy may retard the progession of diabetic nephropathy. Diabetologia, 1995, 38:604.
  • 10Shoji T, Nishizawa Y, Toyokawa A, et al.Decreased abluminuria by pravastain in hyperlipidemic diabetics. Nephron, 1991, 59:664.

共引文献55

同被引文献24

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部